bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S6 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Table S6
Supplementary Data from Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
Authors: Westphalen C. Benedikt , Fine Alexander D. , André Fabrice , Ganesan Shridar , Heinemann Volker , Rouleau Etienne , Turnbull Clare , Garcia Palacios Luis , Lopez Jorge-Antonio , Sokol Ethan S. , Mateo Joaquin
Published: April 2023

Supplementary Data from Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Authors: Xu Jihong , Wu Pei-Jung , Lai Tzung-Huei , Sharma Pratibha , Canella Alessandro , Welker Alessandra M. , Beattie Christine E. , Elder J. Brad , Easley Michelle , Lonser Russell , Jacob Naduparambil K. , Pietrzak Maciej , Timmers Cynthia M. , Lang Frederick , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Authors: George Suzanne , von Mehren Margaret , Fletcher Jonathan A. , Sun Jichao , Zhang Sen , Pritchard Justin R. , Hodgson John Graeme , Kerstein David , Rivera Victor M. , Haluska Frank G. , Heinrich Michael C.
Published: April 2023

Supplementary Data from Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplement Appendix 2: Chemotherapy Dose Adjustments.
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Son Jieun , Okoro Jeffrey J. , Mira Alessia , Patrucco Enrico , Eum Yoonji , Wang Xinan , Paranal Raymond , Wang Haiyun , Lin Mika , Haikala Heidi M. , Li Jiaqi , Xu Yue , Alessi Joao Victor , Chhoeu Chhayheng , Redig Amanda J. , Köhler Jens , Dholakia Kshiti H. , Chen Yunhan , Richard Elodie , Nokin Marie-Julie , Santamaria David , Gokhale Prafulla C. , Awad Mark M. , Jänne Pasi A. , Ambrogio Chiara
Published: April 2023

Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer
Supplementary Data from The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Authors: Manca Paolo , Corallo Salvatore , Busico Adele , Lonardi Sara , Corti Francesca , Antoniotti Carlotta , Procaccio Letizia , Clavarezza Matteo , Smiroldo Valeria , Tomasello Gianluca , Murialdo Roberto , Sartore-Bianchi Andrea , Racca Patrizia , Pagani Filippo , Randon Giovanni , Martinetti Antonia , Sottotetti Elisa , Palermo Federica , Perrone Federica , Tamborini Elena , Prisciandaro Michele , Raimondi Alessandra , Di Bartolomeo Maria , Morano Federica , Pietrantonio Filippo
Published: April 2023

Suppl Fig 1
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplemental Appendix 6. Summary of ddPCR mutations to yield highest sensitivity for ctDNA detection.
Supplementary Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Authors: Monjazeb Arta M. , Giobbie-Hurder Anita , Lako Ana , Thrash Emily M. , Brennick Ryan C. , Kao Katrina Z. , Manuszak Claire , Gentzler Ryan D. , Tesfaye Anteneh , Jabbour Salma K. , Alese Olatunji B. , Rahma Osama E. , Cleary James M. , Sharon Elad , Mamon Harvey J. , Cho May , Streicher Howard , Chen Helen X. , Ahmed Mansoor M. , Mariño-Enríquez Adrian , Kim-Schulze Seunghee , Gnjatic Sacha , Maverakis Emanual , Marusina Alina I. , Merleev Alexander A. , Severgnini Mariano , Pfaff Kathleen L. , Lindsay James , Weirather Jason L. , Ranasinghe Srinika , Spektor Alexander , Rodig Scott J. , Hodi F. Stephen , Schoenfeld Jonathan D.
Published: April 2023

Supplementary Data and Methods
Supplementary Table 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Authors: Zhang Henan , Orme Jacob J. , Abraha Feven , Stish B.J. , Lowe Val J. , Lucien Fabrice , Tryggestad Erik J. , Bold Michael S. , Pagliaro Lance C. , Choo C. Richard , Brinkmann Debra H. , Iott Matthew J. , Davis Brian J. , Quevedo J. Fernando , Harmsen William S. , Costello Brian A. , Johnson Geoffrey B. , Nathan Mark A. , Olivier Kenneth R. , Pisansky Thomas M. , Kwon Eugene D. , Dong Haidong , Park Sean S.
Published: April 2023

Supplementary Table 3. Baseline TTR and changes after SBRT predict outcomes in oligometastatic CRPC. Median event-free survival survival (in months) and hazard ratio for each outcome and group is given, stratified by baseline TTR levels (left) or change in TTR levels from baseline to day 14 post-SBRT. ns not significant; N/A not applicable
Supplementary Table 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Authors: Zhang Henan , Orme Jacob J. , Abraha Feven , Stish B.J. , Lowe Val J. , Lucien Fabrice , Tryggestad Erik J. , Bold Michael S. , Pagliaro Lance C. , Choo C. Richard , Brinkmann Debra H. , Iott Matthew J. , Davis Brian J. , Quevedo J. Fernando , Harmsen William S. , Costello Brian A. , Johnson Geoffrey B. , Nathan Mark A. , Olivier Kenneth R. , Pisansky Thomas M. , Kwon Eugene D. , Dong Haidong , Park Sean S.
Published: April 2023

Supplementary Table 2. Distant radiographic progression by number of sites treated. 1Kaplan-Meier method; 2Cox model; 3Logrank test; 4Wald Chi-Square test.
Supplementary Figure 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Authors: Zhang Henan , Orme Jacob J. , Abraha Feven , Stish B.J. , Lowe Val J. , Lucien Fabrice , Tryggestad Erik J. , Bold Michael S. , Pagliaro Lance C. , Choo C. Richard , Brinkmann Debra H. , Iott Matthew J. , Davis Brian J. , Quevedo J. Fernando , Harmsen William S. , Costello Brian A. , Johnson Geoffrey B. , Nathan Mark A. , Olivier Kenneth R. , Pisansky Thomas M. , Kwon Eugene D. , Dong Haidong , Park Sean S.
Published: April 2023

Supplementary Figure 2. Flow cytometry gating strategies. (A) Flow cytometry gating strategies of central memory (TCM), effector memory (TEM), effector (TEF), and naïve (TN) T-cells populations. (B) Flow cytometry gating strategies of tumor reactive (TTR, CD8+CD11ahigh) T cell population analysis.
Supplementary Figure 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Authors: Zhang Henan , Orme Jacob J. , Abraha Feven , Stish B.J. , Lowe Val J. , Lucien Fabrice , Tryggestad Erik J. , Bold Michael S. , Pagliaro Lance C. , Choo C. Richard , Brinkmann Debra H. , Iott Matthew J. , Davis Brian J. , Quevedo J. Fernando , Harmsen William S. , Costello Brian A. , Johnson Geoffrey B. , Nathan Mark A. , Olivier Kenneth R. , Pisansky Thomas M. , Kwon Eugene D. , Dong Haidong , Park Sean S.
Published: April 2023

Supplementary Figure 1. PSA and distant progression by number of radiation-treated sites. (A) PSA progression by number of sites treated. (B) Distant radiographic progression by number of sites treated.
Supplementary Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Authors: Nguyen Cong Trung , Caruso Stefano , Maille Pascale , Beaufrère Aurélie , Augustin Jérémy , Favre Loetitia , Pujals Anaïs , Boulagnon-Rombi Camille , Rhaiem Rami , Amaddeo Giuliana , di Tommaso Luca , Luciani Alain , Regnault Hélène , Brustia Raffaele , Scatton Olivier , Charlotte Frédéric , Brochériou Isabelle , Sommacale Daniele , Soussan Patrick , Leroy Vincent , Laurent Alexis , Le Van Ky , Ta Van To , Trinh Hong Son , Tran Thi Lan , Gentien David , Rapinat Audrey , Nault Jean Charles , Allaire Manon , Mulé Sebastien , Zucman-Rossi Jessica , Pawlotsky Jean-Michel , Tournigand Christophe , Lafdil Fouad , Paradis Valérie , Calderaro Julien
Published: April 2023

Supplemental figures 1-10
Supplementary Methods from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition
Authors: Zhang Pu , Brinton Lindsey T. , Williams Katie , Sher Steven , Orwick Shelley , Tzung-Huei Lai , Mims Alice S. , Coss Christopher C. , Kulp Samuel K. , Youssef Youssef , Chan Wing Keung , Mitchell Shaneice , Mustonen Allison , Cannon Matthew , Phillips Hannah , Lehman Amy M. , Kauffman Tierney , Beaver Larry , Canfield Daniel , Grieselhuber Nicole R. , Alinari Lapo , Sampath Deepa , Yan Pearlly , Byrd John C. , Blachly James S. , Lapalombella Rosa
Published: April 2023

Supplementary Methods
Supplementary Table S1 from Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group
Authors: Spira Alexander I. , Stewart Mark D. , Jones Suzanne , Chang Elaine , Fielding Anitra , Richie Nicole , Wood Laura S. , Thompson Michael A. , Jones Lee , Nair Abhilasha , Mahal Brandon A. , Gerber David E.
Published: April 2023

Published manuscripts supporting 23 of the 26 approvals were retrieved (as of March 2020) and the eligibility criteria specifics for each trial were extracted from each manuscript.
Supplementary Data from Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
Authors: Batool Syeda Maheen , Muralidharan Koushik , Hsia Tiffany , Falotico Sarah , Gamblin Austin S. , Rosenfeld Yulia B. , Khanna Sirena K. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Data from Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
Supplementary Table from Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Authors: Noh Joseph J. , Cho Young-Jae , Ryu Ji-Yoon , Choi Jung-Joo , Hwang Jae Ryoung , Choi Ju-Yeon , Lee Jeong-Won
Published: April 2023

Supplementary Table from Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
Supplementary Data from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Authors: Denize Thomas , Hou Yue , Pignon Jean-Christophe , Walton Emily , West Destiny J. , Freeman Gordon J. , Braun David A. , Wu Catherine J. , Gupta Saurabh , Motzer Robert J. , Atkins Michael B. , McDermott David , Choueiri Toni K. , Shukla Sachet A. , Signoretti Sabina
Published: April 2023

Supplementary Data from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Supplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Authors: Brashears Caitlyn B. , Prudner Bethany C. , Rathore Richa , Caldwell Katharine E. , Dehner Carina A. , Buchanan Jane L. , Lange Sara E.S. , Poulin Neal , Sehn Jennifer K. , Roszik Jason , Spitzer Dirk , Jones Kevin B. , O'Keefe Regis , Nielsen Torsten O. , Taylor Eric B. , Held Jason M. , Hawkins William , Van Tine Brian A.
Published: April 2023

Supplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Supplementary Data from FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Authors: Przepiorka Donna , Le Robert Q. , Ionan Alexei , Li Ruo-Jing , Wang Ying-Hong , Gudi Ramadevi , Mitra Soumya , Vallejo Jonathon , Okusanya Olanrewaju O. , Ma Lian , Yang Yuching , Patel Paresma , Mezaache Djelila , Shah Rakhi , Banerjee Anamitro , McLamore Sherita , Maung Adam N. , Goldberg Kirsten B. , Pazdur Richard , Theoret Marc R. , De Claro R. Angelo
Published: April 2023

Supplementary Data from FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Supplementary Table from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Authors: Vesely Clare , Wong Yien Ning Sophia , Childs Alexa , Akarca Ayse U. , Dhami Pawan , Vaikkinen Heli , Conde Lucia , Herrero Javier , Ogunbiyi Olagunju , Gander Amir , Luong Tu Vinh , Thirlwell Chrissie , Caplin Martyn , Toumpanakis Christos , Peggs Karl , Quezada Sergio A. , Marafioti Teresa , Meyer Tim
Published: April 2023

Supplementary Table from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Supplementary Table from Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Authors: Suman Vera J. , Du Lili , Hoskin Tanya , Anurag Meenakshi , Ma Cynthia , Bedrosian Isabelle , Hunt Kelly K. , Ellis Matthew J. , Symmans W. Fraser
Published: April 2023

Supplementary Table from Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Supplementary Data from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Authors: Shah Manish A. , Shitara Kohei , Lordick Florian , Bang Yung-Jue , Tebbutt Niall C. , Metges Jean-Phillippe , Muro Kei , Lee Keun-Wook , Shen Lin , Tjulandin Sergei , Hays John L. , Starling Naureen , Xu Rui-Hua , Sturtz Keren , Fontaine Marilyn , Oh Cindy , Brooks Emily M. , Xu Bo , Li Wei , Li Chiang J. , Borodyansky Laura , Van Cutsem Eric
Published: April 2023

Supplementary Data from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Supplementary tables from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Authors: Song Zhengbo , Lv Dongqing , Chen Shi-Qing , Huang Jianjin , Li Yuping , Ying Shenpeng , Wu Xiaoyu , Hua Feng , Wang Wenxian , Xu Chunwei , Bei Ting , Gao Chan , Sun Zhijian , Zhang Yiping , Lu Shun
Published: April 2023

Supplementary tables
Supplementary Table from FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Authors: Kim Nina , Norsworthy Kelly J. , Subramaniam Sriram , Chen Haiyan , Manning Michael L. , Kitabi Eliford , Earp Justin , Ehrlich Lori A. , Okusanya Olanrewaju O. , Vallejo Jonathon , Gehrke Brenda J. , de Claro R. Angelo , Pazdur Richard
Published: April 2023

Supplementary Table from FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Authors: Radovich Milan , Solzak Jeffrey P. , Wang Chao J. , Hancock Bradley A. , Badve Sunil , Althouse Sandra K. , Bray Steven M. , Storniolo Anna Maria V. , Ballinger Tarah J. , Schneider Bryan P. , Miller Kathy D.
Published: April 2023

Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Authors: Chen Li , Jiang Yi-Zhou , Wu Song-Yang , Wu Jiong , Di Gen-Hong , Liu Guang-Yu , Yu Ke-Da , Fan Lei , Li Jun-Jie , Hou Yi-Feng , Hu Zhen , Chen Can-Ming , Huang Xiao-Yan , Cao A-Yong , Hu Xin , Zhao Shen , Ma Xiao-Yan , Xu Ying , Sun Xiang-Jie , Chai Wen-Jun , Guo Xiaomao , Chen Xizi , Xu Yanhui , Zhu Xiao-Yu , Zou Jian-Jun , Yang Wen-Tao , Wang Zhong-Hua , Shao Zhi-Ming
Published: April 2023

Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Table from Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Authors: Majem Margarita , Goldman Jonathan W. , John Thomas , Grohe Christian , Laktionov Konstantin , Kim Sang-We , Kato Terufumi , Vu Huu Vinh , Lu Shun , Li Shanqing , Lee Kye Young , Akewanlop Charuwan , Yu Chong-Jen , de Marinis Filippo , Bonanno Laura , Domine Manuel , Shepherd Frances A. , Atagi Shinji , Zeng Lingmin , Kulkarni Dakshayini , Medic Nenad , Tsuboi Masahiro , Herbst Roy S. , Wu Yi-Long
Published: April 2023

Supplementary Table from Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
Authors: Bartlett John M.S. , Sgroi Dennis C. , Treuner Kai , Zhang Yi , Piper Tammy , Salunga Ranelle C. , Ahmed Ikhlaaq , Doos Lucy , Thornber Sarah , Taylor Karen J. , Brachtel Elena F. , Pirrie Sarah J. , Schnabel Catherine A. , Rea Daniel W.
Published: April 2023

Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
Supplementary Figure from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells
Authors: Goff Peter H. , Riolobos Laura , LaFleur Bonnie J. , Spraker Matthew B. , Seo Y. David , Smythe Kimberly S. , Campbell Jean S. , Pierce Robert H. , Zhang Yuzheng , He Qianchuan , Kim Edward Y. , Schaub Stephanie K. , Kane Gabrielle M. , Mantilla Jose G. , Chen Eleanor Y. , Ricciotti Robert , Thompson Matthew J. , Cranmer Lee D. , Wagner Michael J. , Loggers Elizabeth T. , Jones Robin L. , Murphy Erin , Blumenschein Wendy M. , McClanahan Terrill K. , Earls Jon , Flanagan Kevin C. , LaFranzo Natalie A. , Kim Teresa S. , Pollack Seth M.
Published: April 2023

Supplementary Figure from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells
Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Authors: An Jusheng , Tang Jie , Li Benjamin X. , Xiong Huihua , Qiu Hui , Luo Lin , Wang Li , Wang Danbo , Zhou Qi , Xu Qin , Song Honglin , Zhang Yunyan , Zhang Hongping , Li Yujie , Yu Xiaohui , Zhang Jing , Ng Rachel , Zhao Wayne , Wong Michael , Dai Xiangrong , Li Guiling , Wu Lingying
Published: April 2023

Research Protocol for the Phase I Clinical Study of the Recombinant Fully Human Anti-PD-L1 Monoclonal Antibody Socazolimab
Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 1B
Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Copy Number
Supplementary Figure S6 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

EBNA1 protein sequences from NPC tumors compared to the Akata or B95-8 reference strains.
Conservation plots of EBNA1 amino acid sequences comparing NPC tumors to Akata (left column) and B95-8 (right column). The NPC tumor-derived sequences are grouped by geographic region (endemic - China, Hong Kong, and Indonesia; non-endemic China). The number of tumor-derived sequences included in each alignment are shown in parentheses. EBNA1 regions of interest are labeled – N-Terminus, Glycine-Alanine repeat region (Gly-Ala Repeat), Nuclear Localization Signal (NLS), Immunodominant Epitope (IDE), DNA Binding Domain (DBD), Dimerization Motif (Dimer 1 and 2). Red arrows denote residues that are deviant from the reference strain in the IDE.
Supplementary Figure S4 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

IgA detection of select EBV proteins in sera from incident NPC cases and healthy controls in the SCHS and SCS cohorts.
Heatmap depicting normalized detection of IgAH against 8 EBV proteins identified in the NPC differential IgA panel (Fig 3) from (A) 20 SCHS pairs from the discovery group or (B) 31 pairs up to 10 years prior to NPC diagnosis from the SCHS and SCS validation groups. All samples were previously tested for EBNA1 IgA and status is shown as positive (+) or negative (-). Fisher’s exact test identifies proteins (bolded) that discriminate case from controls and denoted *p<0.05.
Supplementary Figure S3 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

Detection of EBV-specific IgM in sera from incident NPC cases and healthy controls in the SCHS cohort.
Heatmap depicting IgM heavy chain-specific (IgMH) normalized detection values from 20 incident NPC case-control pairs and the data is represented similarly to Fig 2 with Fisher’s exact test identifying no protein that discriminated case from controls.
Supplementary Figures 1-3 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
Authors: Ge Huaibin , Ferris Robert L. , Wang Jing H.
Published: April 2023

Supplementary Figure 1-3
Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Authors: Sugimoto Akira , Matsumoto Shingo , Udagawa Hibiki , Itotani Ryo , Usui Yuko , Umemura Shigeki , Nishino Kazumi , Nakachi Ichiro , Kuyama Shoichi , Daga Haruko , Hara Satoshi , Miyamoto Shingo , Kato Terufumi , Sakakibara-Konishi Jun , Tabata Eriko , Nakagawa Taku , Kawaguchi Tomoya , Sakai Tetsuya , Shibata Yuji , Izumi Hiroki , Nosaki Kaname , Zenke Yoshitaka , Yoh Kiyotaka , Goto Koichi
Published: April 2023

Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Authors: Sugimoto Akira , Matsumoto Shingo , Udagawa Hibiki , Itotani Ryo , Usui Yuko , Umemura Shigeki , Nishino Kazumi , Nakachi Ichiro , Kuyama Shoichi , Daga Haruko , Hara Satoshi , Miyamoto Shingo , Kato Terufumi , Sakakibara-Konishi Jun , Tabata Eriko , Nakagawa Taku , Kawaguchi Tomoya , Sakai Tetsuya , Shibata Yuji , Izumi Hiroki , Nosaki Kaname , Zenke Yoshitaka , Yoh Kiyotaka , Goto Koichi
Published: April 2023

Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Figure from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Authors: Benhamouda Nadine , Sam Ikuan , Epaillard Nicolas , Gey Alain , Phan Letuan , Pham Hang Phuong , Gruel Nadège , Saldmann Antonin , Pineau Joséphine , Hasan Milena , Quiniou Valentin , Nevoret Camille , Verkarre Virginie , Libri Valentina , Mella Sebastien , Granier Clémence , Broudin Chloe , Ravel Patrice , De Guillebon Eléonore , Mauge Laetitia , Helley Dominique , Jabla Bernd , Chaput Nathalie , Albiges Laurence , Katsahian Sandrine , Adam Julien , Mejean Arnaud , Adotevi Olivier , Vano Yann A. , Oudard Stéphane , Tartour Eric
Published: April 2023

Supplementary Figure from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Supplementary Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Authors: Davis Kara L. , Fox Elizabeth , Isikwei Emasenyie , Reid Joel M. , Liu Xiaowei , Minard Charles G. , Voss Stephan , Berg Stacey L. , Weigel Brenda J. , Mackall Crystal L.
Published: April 2023

Supplementary information
Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Predicted TSA/TAA-derived N-peptides and D-neopeptides
Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Activated T lymphocytes in recurrent tumor interact with macrophages. (A) Expression of T cell activating markers HLA-DR and Tim-3 in the perivascular areas and peritumoral areas of the primary and recurrent tumor was detected by IMC. (B) CD3-CD7+ NK cells infiltrated in the perivascular areas and peritumoral areas of the primary and recurrent tumor was detected by IMC. (C) Pro-inflammatory CD11c+ CD68+ macrophages, which had infiltrated the perivascular areas and peritumoral areas of the primary and recurrent tumor, were detected by IMC. (D) Colocalization analysis of CD68+ macrophages and CD3+ T cells in the perivascular areas and peritumoral areas of the primary and recurrent tumor were detected by IMC. Scale bars are indicated in the figures.
Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

PBMCs collected before vaccination show low/no response to candidate vaccine peptides. (A) The nomenclature of the N-peptides and D-neopeptides. I or II indicate if the peptides were chosen/designed for HLA class I or -II binding; MUT/RNA/GBM indicates a naturally mutated peptide (MUT), derivation from the over-/highly expressed genes (RNA) or from known glioblastoma (GBM) targets; X indicates the number of the peptide; 0 or 1 indicate if the peptides had been artificially mutated (1) or not (0); (’) indicates that peptides contained the naturally mutated amino acid. (B) PBMCs collected before vaccination were stimulated with 4 μg/mL Tetanus toxoid or 2 μM CEF II peptide pool for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. The proliferation strength is depicted as counts per minute (cpm). In each group, the N-peptides and their corresponding D-neopeptides are included, and the designed mutated positions are highlighted in the red box. The blue dotted line indicates the mean value of the no peptide control. The red dotted line indicates the mean value plus three standard deviations of the no peptide control. Values above the red dotted line were considered positive. (C) PBMCs collected before vaccination were stimulated with 5 μM predicted class I-peptides, including N-peptides and D-neopeptides, for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. 10-15 replicate wells were tested for proliferation, and responses were depicted as cpm. (D) PBMCs collected before vaccination were stimulated with 5 μM predicted class II-peptides, including N-peptides and D-neopeptides, for 7 days, and proliferation was measured by ³H-thymidine incorporation assay. 10-15 replicate wells were tested for proliferation, and responses were depicted as cpm.
Supplementary Figures S1-S11 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Authors: Peng Ke , Zhang Feifei , Wang Yichen , Sahgal Pranshu , Li Tianxia , Zhou Jin , Liang Xiaoyan , Zhang Yanxi , Sethi Nilay , Liu Tianshu , Zhang Haisheng , Bass Adam J.
Published: April 2023

Supplementary figure 1. CDK6 overexpression promotes FAK inhibitor resistance in SNU668.
Supplementary figure 2. CDK4/6 inhibitor enhanced the efficacy of FAK inhibitors in Cdh1-/-RHOAY42C/+ organoids.
Supplementary figure 3. Combination of defactinib and palbociclib in patient-derived organoids (PDOs).
Supplementary figure 4. CDK4/6 inhibitor enhanced the efficacy of FAK inhibitors in DGC cell lines.
Supplementary figure 5. In vivo experiment of VS-4718 and Palbociclib combination.
Supplementary figure 6. FAK inhibitor VS-4718 induces MAPK activation in DGC organoids and cell lines.
Supplementary figure 7. Phospho-RTK and RAS-GTP detection in Cdh1-/-RHOAY42C/+ organoids treated with FAK inhibitors.
Supplementary figure 8. MAPK inhibitor and FAK inhibitor have synergistic effect in Cdh1-/-RHOAY42C/+ organoids.
Supplementary figure 9. MAPK inhibitor and FAK inhibitor have synergistic effect in PDOs.
Supplementary figure 10. MAPK inhibitor and FAK inhibitor have synergistic effect in DGC cell lines.
Supplementary figure 11. In vivo experiment of VS-4718 with VS-6766 or palbociclib combination.
Figure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Authors: Kang Kyung-Don , Bernstock Joshua D. , Totsch Stacie K. , Gary Sam E. , Rocco Abbey , Nan Li , Li Rong , Etminan Tina , Han Xiaosi , Beierle Elizabeth A. , Eisemann Tanja , Wechsler-Reya Robert J. , Bae Sejong , Whitley Richard , Gillespie G. Yancey , Markert James M. , Friedman Gregory K.
Published: April 2023

Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
Authors: Rochigneux Philippe , Lisberg Aaron , Garcia Alejandro , Granjeaud Samuel , Madroszyk Anne , Fattori Stéphane , Gonçalves Anthony , Devillier Raynier , Maby Pauline , Salem Nassim , Gorvel Laurent , Chanez Brice , Gukasyan Jaklin , Carroll James , Goldman Jonathan , Chretien Anne Sophie , Olive Daniel , Garon Edward B.
Published: April 2023

Supplementary Table 1: List of antibodies used in the mass cytometry panel
Supplementary Table 2: Number of immune cells analysed by CYTOF in our cohort
Supplementary Table 3: Demographic and clinical characteristics of the CyTOF UCLA cohort (n=27), the Total UCLA cohort (n=97) and the Total KEYNOTE-001 (n=495) of non-small cell lung cancer patients
Supplementary Table 4: Cox's proportional hazards model for overall survival in NSCLC patients treated with pembrolizumab in KEYNOTE-001
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Authors: Kebir Sied , Ullrich Vivien , Berger Pia , Dobersalske Celia , Langer Sarah , Rauschenbach Laurèl , Trageser Daniel , Till Andreas , Lorbeer Franziska K. , Wieland Anja , Wilhelm-Buchstab Timo , Ahmad Ashar , Fröhlich Holger , Cima Igor , Prasad Shruthi , Matschke Johann , Jendrossek Verena , Remke Marc , Grüner Barbara M. , Roesch Alexander , Siveke Jens T. , Herold-Mende Christel , Blau Tobias , Keyvani Kathy , van Landeghem Frank K.H. , Pietsch Torsten , Felsberg Jörg , Reifenberger Guido , Weller Michael , Sure Ulrich , Brüstle Oliver , Simon Matthias , Glas Martin , Scheffler Björn
Published: April 2023

Extended Data relating to Main Figure 3/AKT-driven progression of ALDH1A1+ cells in glioblastoma. A, Flow cytometry histograms showing ALDH1A1 expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3A. Isotype controls in gray. B, Flow cytometry histograms of ALDH1A1 derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data quantification in Supplementary Fig. S2B. C, Cartoon illustrating course of neurosphere experiments, quantified in main Fig. 3B and in Supplementary Fig. S3D, applying treatment-naive and paired experimental and clinical relapse patient cells. Right: Exemplary qRT-PCR data presenting knockdown efficacy of the siRNA approach in respective cells, normalized to siNT control. Mean of duplicates ± SD. D, Source data for Fig. 3B, and for Supplementary Fig. S3E. Dotplots show percent neurosphere-forming cells estimated from neurospheres at 12 days after seeding. Paired patient cell analysis, evaluating 1° and 2° neurospheres of indicated knockdown (siALDH1A1) and respective control (siNT) cell samples. Data shown as mean ± SD. E, Neurosphere assay, similar to main Fig. 3B on paired treatment-naive vs. experimental relapse (TMZ→eR) BN46 cells. Source data in Supplementary Fig. S3D. Data as mean ± SD. F, Protein patterns, similar to Fig. 3D. on paired cells from 2 additional discovery cohort samples. G, Flow cytometry histograms depicting pAKT(Ser473) expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3E. Isotype controls in gray. H, Flow cytometry histograms of pAKT(Ser473) and, right, quantification of data derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data represent mean fluorescence intensities (MFI), ± SD, normalized to isotype control (gray). I, Representative source data for Fig. 3F. Flow cytometry profiles of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. clinical relapse cell samples. J, Flow cytometry profiles of of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. experimental relapse conditions of BN46 cells (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)).
Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.
Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

Immune cell analysis by BMI.
A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the MD Anderson Cancer Center (MDA) cohort. Line represents median +/- interquartile range; each dot represents a single tumor.
B. IHC analysis for PD-L1-, CD45RO-, FOXP3-, EOMES-, GZMB-, PD-1-, TBET-, and TBET:FOXP3-positive cells in OW/OB verse NL tumors as defined by body mass index from the Gide cohort. Line represents median +/- interquartile range; each dot represents a single tumor.
Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Authors: Marmouset Vincent , Decroocq Justine , Garciaz Sylvain , Etienne Gabriel , Belhabri Amine , Bertoli Sarah , Gastaud Lauris , Simand Célestine , Chantepie Sylvain , Uzunov Madalina , Genthon Alexis , Berthon Céline , Chiche Edmond , Dumas Pierre-Yves , Vargaftig Jacques , Salmeron Géraldine , Lemasle Emilie , Tavernier Emmanuelle , Delage Jérémy , Loirat Marion , Morineau Nadine , Blanc-Durand Félix , Pautier Patricia , Vergé Véronique , Auger Nathalie , Thomas Myrtille , Stefani Laetitia , Lepelley Marion , Boyer Thomas , Thepot Sylvain , Gourin Marie-Pierre , Bourquard Pascal , Duchmann Matthieu , Morice Pierre-Marie , Michallet Mauricette , Adès Lionel , Fenaux Pierre , Récher Christian , Dombret Hervé , Pagès Arnaud , Marzac Christophe , Leary Alexandra , Micol Jean-Baptiste
Published: April 2023

Univariate analysis for overall survival from t-MN diagnosis of patients from the national cohort.
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Authors: Marmouset Vincent , Decroocq Justine , Garciaz Sylvain , Etienne Gabriel , Belhabri Amine , Bertoli Sarah , Gastaud Lauris , Simand Célestine , Chantepie Sylvain , Uzunov Madalina , Genthon Alexis , Berthon Céline , Chiche Edmond , Dumas Pierre-Yves , Vargaftig Jacques , Salmeron Géraldine , Lemasle Emilie , Tavernier Emmanuelle , Delage Jérémy , Loirat Marion , Morineau Nadine , Blanc-Durand Félix , Pautier Patricia , Vergé Véronique , Auger Nathalie , Thomas Myrtille , Stefani Laetitia , Lepelley Marion , Boyer Thomas , Thepot Sylvain , Gourin Marie-Pierre , Bourquard Pascal , Duchmann Matthieu , Morice Pierre-Marie , Michallet Mauricette , Adès Lionel , Fenaux Pierre , Récher Christian , Dombret Hervé , Pagès Arnaud , Marzac Christophe , Leary Alexandra , Micol Jean-Baptiste
Published: April 2023

Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Genomic alterations identified in CCA_PDXs by an in-house next-generation sequencing (NGS) with a custom 435-gene hybrid capture-based panel.
Supplementary Data from A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
Authors: Han Kathy , Fyles Anthony , Shek Tina , Croke Jennifer , Dhani Neesha , D'Souza David , Lee Ting-Yim , Chaudary Naz , Bruce Jeffrey , Pintilie Melania , Cairns Rob , Vines Douglass , Pakbaz Sara , Jaffray David , Metser Ur , Rouzbahman Marjan , Milosevic Michael , Koritzinsky Marianne
Published: April 2023

Supplementary Data from A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Genomic alterations identified in CCA_biopsies by FoundationOne